Since the pandemic, BioNTech (BNTX) has become a household name. In the meantime, investors have really enjoyed the Mainz-based company’s stock. It’s currently probably one of the best-known shares on the German stock market.
But as we all know, the stock market is not a one-way street, as the stock’s chart impressively demonstrates.
Its record high was just under 400 euros ($456) in the summer of last year. But the share price has more than halved and is currently hovering around 199 euros ($227).
No More Gains for BioNTech?
At present, BioNTech’s COVID-19 vaccine business is unlikely to reach full speed for a long time. After all, the number of infections worldwide remains at an extremely high level in the new year.
Every day, the media is full of reports about new infection figures or even new coronavirus variants. The enormous demand for vaccines therefore continues to play into the hands of companies such as BioNTech and could sooner or later help the share to gain momentum again.
More Than Just a Vaccine Developer
In addition, the biotechnology group is so much more than just a COVID-19 vaccine manufacturer. Many people are probably not even aware that the Corminaty vaccine against COVID-19 is not the only one in the company’s repertoire; mRNA vaccines against influenza, malaria, HIV and cancer are also in development.
Corona booster vaccines could and, by all accounts, probably will be needed for some time to come. This should provide the BioNTech group with good sales figures. Additional share price fireworks could also be triggered at any time by further mRNA vaccines reaching approval.